American Society for Nephrology Kidney Week, Nov 5-10, 2019.

From the embargo policy page:

"Titles of accepted late-breaking clinical trials will be posted online on October 11, 2019."

CKD Sub-Study? As long as they don't present anything that violates the AHA Embargo, I think seeing the CKD Sub-Study results here is very likely. We'll know soon this Friday.

Chronic kidney disease sub-study to look at change in eGFR

Changes in eGFR in those patients with baseline eGFR below 60 mL/min will be examined as a secondary endpoint (see sub-study poster here). In a post-hoc analysis of ASSURE and SUSTAIN,"Patients who received apabetalone (n=35) versus placebo (n=13) over 6 months showed significantly (p=0.02) lowered serum ALP -14.0% (p<0.0001 versus baseline) versus -6.3% (p=0.9 versus baseline). The eGFR in the apabetalone group increased by 3.4% (1.7 mL/min/1.73 m2) (p=0.04 versus baseline) and decreased by 5.8% (2.9 mL/min/1.73 m2) (p=0.6 versus baseline) in the placebo group. Apabetalone was well tolerated." This was published in this paper "Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease." Apabetalone has also been shown to elicit huge effects on the plasma proteome in stage 4/5 CKD patients after a single dose as detailed in this paper "Benefit of Apabetalone on Plasma Proteins in Renal Disease." So tons of potential here in renal disease. They have also pre-specified looking at the primary 3-point MACE endpoint in those with eGFR >60 mL/min and < 60 mL/min. 

BDAZ